Retatrutide vs Tirzepatide: What 2026 Trials Actually Show
Retatrutide produced the larger weight-loss percentage in the selected placebo-controlled trials, but these separate studies cannot establish that it outperforms tirzepatide. The 2026 retatrutide figures of 25.0% and 28.3% answer different statistical questions. As checked on 13 October 2026, the registered direct comparison had no posted results.
What changed in 2026?
The important update is the phase 3 TRIUMPH-1 paper, published in the New England Journal of Medicine on 29 September 2026. It moves the discussion beyond retatrutide’s early clinical studies. It also makes the analysis behind each headline essential reading: a trial can legitimately produce more than one estimate of weight change.
This comparison focuses on adult weight-management evidence without diabetes. SURMOUNT-1 supplies a clearly defined tirzepatide benchmark, published in 2022. These selected trials answer a narrower question than the entire development programmes. Diabetes trials, studies in specific complications and longer extension cohorts need separate interpretation.
What is the difference between the two molecules?
Tirzepatide activates GIP and GLP-1 receptors. Retatrutide activates those receptors plus the glucagon receptor. Retatrutide is one molecule with three receptor targets; “triple agonist” does not describe a mixture of three drugs. The additional target explains scientific interest in comparing the compounds.
Receptor count alone cannot tell us which treatment produces better outcomes, which effects come from a particular receptor, or how tolerability compares. Those questions require clinical evidence. Neither the mechanism nor a large weight-loss average establishes the best choice for an individual.
The weight-loss results, with the missing context restored
The table uses treatment-regimen results for each trial’s highest studied maintenance-dose arm. Percentages are average reductions from starting weight, not the share of participants who lost weight. The sample sizes refer to the whole randomized trial across all arms, including placebo; they are not the denominators for the highest-dose groups.
Both were randomized, double-blind, placebo-controlled phase 3 trials. Keeping the analysis category aligned improves the comparison, but it does not make participants from separate trials interchangeable.
| Trial detail | Retatrutide: TRIUMPH-1 | Tirzepatide: SURMOUNT-1 |
|---|---|---|
| Publication | 2026 | 2022 |
| Total randomized | 2,339 across four arms | 2,539 across four arms |
| Population | Adults with obesity or qualifying overweight; diabetes excluded | Adults with obesity or qualifying overweight; diabetes excluded |
| Weight endpoint | 80 weeks | 72 weeks |
| Mean baseline weight | 112.7 kg | 104.8 kg |
| Analysis shown | Treatment-regimen estimand | Treatment-regimen estimand |
| Highest-arm average weight reduction | 25.0% | 20.9% |
| Placebo average weight reduction | 3.9% | 3.1% |
Why do retatrutide headlines say both 25.0% and 28.3%?
An estimand is the precise treatment-effect question a trial sets out to answer. Its definition includes the population, outcome and handling of events such as stopping treatment or starting another weight-management intervention. Changing that question can change the estimate even when the trial is the same.
In TRIUMPH-1, 28.3% is the efficacy estimate, assuming continued study treatment without prohibited weight-management interventions. Its 25.0% treatment-regimen estimate allows for non-adherence or those interventions. Lilly’s definition of continued treatment permits specified treatment modifications.
The larger figure is therefore not a replacement for the smaller one. Read the analysis label beside the percentage. A hypothetical continued-treatment estimate should not be described simply as what happened to everyone enrolled, and an intention-to-treat label does not eliminate assumptions about missing measurements.
Why 25.0% versus 20.9% does not settle the comparison
The trials followed different groups for different lengths of time. TRIUMPH-1’s weight endpoint came eight weeks later, and the average starting weight was higher. Eligibility, treatment changes, participant support and the collection of follow-up measurements also need checking before interpreting a difference between studies.
Randomization balances treatment groups within a trial. It does not balance one trial’s participants against another trial’s participants. Subtracting their averages, or even subtracting each study’s placebo result first, cannot by itself produce a randomized comparison between the two drugs.
A useful reading habit is to ask three questions before accepting a “better” claim: Better for which participants? Measured at what time? Under which analysis? Then check whether the study actually assigned participants between the two treatments. Without that step, the apparent gap is a reason for further investigation rather than a proven comparative effect.
Has retatrutide been compared directly with tirzepatide?
TRIUMPH-5, registered as NCT06662383, is designed to do that. Its record describes a randomized, double-blind phase 3 comparison, estimated enrollment of 800 adults with obesity, and a primary weight-change endpoint at week 80.
As checked on 13 October 2026, ClinicalTrials.gov listed it as active and no longer recruiting, with no results posted. Estimated primary completion was November 2026 and study completion December 2026. Those are study milestones, not promised publication dates. Completed enrollment means recruitment has finished; it does not mean the comparison has reported its findings.
Side effects and stopping treatment belong beside the headline
Gastrointestinal events were prominent in the reported evidence. In Lilly’s May TRIUMPH-1 release, adverse events led to treatment discontinuation in 11.3% of the highest-dose retatrutide group versus 4.9% with placebo. The SURMOUNT-1 abstract reported 6.2% in its highest-dose tirzepatide group versus 2.6% with placebo.
These are adverse-event discontinuations, not all-cause dropout rates or the percentages with missing final measurements. They also cannot establish a safety ranking across separate trials. The retatrutide rates here come from the sponsor’s release; the full published participant-flow and safety tables were not independently assessed for this article.
Lilly’s May release also reported dysesthesia, meaning unusual or altered skin sensations, in 12.5% of the highest-dose retatrutide group versus 0.9% with placebo.
Common-event summaries are only part of safety assessment. Current Zepbound prescribing information includes a boxed warning about thyroid C-cell tumours observed in rodents, with human relevance unknown, plus important warnings involving severe gastrointestinal reactions, pancreatitis, gallbladder disease and dehydration-related kidney injury. Retatrutide’s investigational status leaves its benefit–risk assessment under evaluation.
What would make the next result genuinely more informative?
A direct comparison should report the between-group estimate and its uncertainty, alongside how many participants stopped treatment and how missing outcomes were handled. A headline percentage without those details leaves the central comparison unfinished.
Weight change also cannot answer every health question. A lower number on the scale does not, by itself, establish superior cardiovascular outcomes, preserved muscle function, long-term tolerability or sustained effects after treatment ends. Those claims need their own endpoints and follow-up.
This article uses the accessible primary abstracts, a clearly identified sponsor release, the trial registry and regulatory documents. It is a focused evidence comparison, with no personal dosing, switching or treatment recommendations.
Clinical-trial evidence does not validate separately sold material
The U.S. regulatory distinction is clear: the FDA approved tirzepatide as Zepbound for chronic weight management in 2023; retatrutide remains unapproved in the FDA’s current information. Approval applies to a specified medicine. It does not extend to every product carrying the same ingredient name.
Clinical results concern the trial’s controlled supply, protocol and monitoring. They do not establish the identity, quality, sterility or safety of separately sold research material. A purity result or certificate of analysis cannot bridge that gap. The FDA specifically warns about unapproved products sold for human use under research labels.
For background, the related retatrutide guide below covers foundational 2022–2023 mechanism and early-trial evidence. The testing guides explain a different question: what analytical reports can establish about a submitted sample. None of these pages validates human use of FSD research materials.
Common questions
Is retatrutide better than tirzepatide for weight loss?
The selected separate trials show a larger average reduction with retatrutide, but they cannot establish superiority. A direct randomized comparison is needed; TRIUMPH-5 had no posted results when checked on 13 October 2026.
Is 28.3% the same result as 25.0%?
They are different estimands from the same trial. The efficacy analysis assumes continued treatment under specified conditions; the treatment-regimen analysis allows for non-adherence. Keep the definition beside each percentage.
Is retatrutide FDA-approved in October 2026?
No. As checked on 13 October 2026, retatrutide is not an ingredient in any FDA-approved drug. Positive trial findings do not themselves grant approval or validate products marketed under the same name.
When will the retatrutide-versus-tirzepatide trial report?
The registry estimated primary completion in November 2026 and study completion in December 2026. It did not establish a results-publication date. Follow TRIUMPH-5, NCT06662383, and distinguish completion updates from actual results.
Sources & scope
These references explain analytical and research principles. They do not certify FSD BIO LABS or provide evidence about a particular FSD batch.
- TRIUMPH-1: retatrutide for obesity (29 September 2026) — Jastreboff et al. · New England Journal of Medicine
Primary phase 3 paper; publisher-indexed abstract assessed. Supports randomization, duration and treatment-regimen weight results. Full participant-flow and safety tables were not independently assessed. - SURMOUNT-1: tirzepatide for obesity (2022) — Jastreboff et al. · New England Journal of Medicine
Primary trial abstract assessed through PubMed. Supports population, duration, treatment-regimen weight results and adverse-event discontinuations. - TRIUMPH-1 topline results and analysis definitions (21 May 2026) — Eli Lilly and Company · sponsor release
Sponsor-reported efficacy and treatment-regimen estimates, baseline characteristics and selected safety results. This release is not an independent safety assessment. - TRIUMPH-5: registered retatrutide-versus-tirzepatide trial — ClinicalTrials.gov · NCT06662383
Sponsor-submitted registry record checked 13 October 2026; last update posted 20 July 2026. Documents design, estimated enrollment and completion dates, active status and no posted results. - ICH E9(R1): estimands and sensitivity analysis in clinical trials — International Council for Harmonisation
Official methodological guidance on specifying treatment-effect questions, handling intercurrent events and assessing sensitivity to analysis assumptions. - FDA concerns about unapproved GLP-1 drugs — U.S. Food and Drug Administration
Current regulator page checked 13 October 2026. Supports retatrutide’s unapproved U.S. status and warnings about unapproved products marketed for human use. - FDA approval of Zepbound for chronic weight management (2023) — U.S. Food and Drug Administration
Official original approval announcement and tirzepatide receptor mechanism. Used for approval history, not as the current safety label. - Zepbound prescribing information, revised August 2026 — Eli Lilly and Company · DailyMed
Current prescribing information checked 13 October 2026. Supports selected important risks and the limits of a brief adverse-event summary; no administration guidance is reproduced. - Retatrutide development overview, updated September 2026 — Eli Lilly and Company
Sponsor overview supporting the single-molecule triple-receptor mechanism and development context. It is not independent confirmation of comparative efficacy.